Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AP-101 is an investigational human-derived antibody therapeutic that selectively targets the misfolded ...
Indianapolis' Streets to Home Indy program has housed 114 people and closed three camps in six months of operation, a third of the city's goal.
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 monthsEB613 single tablet final commercial ...
Two federal research and development programs that have infused billions of dollars into fledgling companies and are ...
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose ...
To further expand its global presence and ensure widespread vaccine availability, SII has established Serum Life Sciences Ltd, a subsidiary in the UK. Through relentless pursuit of innovation, SII ...
Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this ...
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.
This award builds on the existing $15.4 million IBAS contract awarded to Kopin in September 2025, further accelerating the company's MicroLED design and manufacturing capabilities. The new SBIR ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Empire State Development (ESD) today announced the 10 startups chosen for round nine of the New York State supported Luminate N ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results